Build status - In Progress
Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 109
  • 373
  • 174
  • 13
  • 16
  • 344
  • 369
  • 4

Found 373 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
The main purpose of this research study is to find out whether Selective Internal Radiation Therapy (SIRT) preceding a standard chemotherapy treatment can improve survival in patients with cholangiocarcinoma in the liver, compared to chemotherapy alone.
 Phase I Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma
99 years or below
All genders
Phase 1
The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study …
 Long-Term Follow-Up Study of Patients Who Have Received Gene-Modified Cell Therapy Produced by Ex Vivo Transduction of Immune Cells Expressing Viral or Non-Viral Vector in Trials
99 years or below
All genders
This is an observational follow-up study of patients who have been exposed to a CAR-T cell treatment that was produced by ex vivo transduction with a CAR-expressing retroviral vector in studies sponsored by Sorrento Therapeutics, Inc. Patients are to be followed for up to 15 years after exposure to a …
 GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)
18 years - 99 years
All genders
This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).
 A Randomized  Multicenter  Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
18 years - 99 years
All genders
Interventional
This study compares 2 combinations of drugs to prevent graft-versus-host disease (GVHD): Tacrolimus/methotrexate and Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best for future transplant patients. The purpose of its companion …
 Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)
18 years - 65 years
All genders
Phase 1
Interventional
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
 CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)
18 years - 99 years
All genders
Phase 3
Interventional
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation in participants with acute leukemia (AML/ALL) or myelodysplastic syndrome (MDS).
18 years - 99 years
All genders
Phase 2
Interventional
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study …
 Study to Assess the Efficacy and Safety of BST-236 in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
18 years - 99 years
All genders
Phase 2
Interventional
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy.
 A  Multicenter Study  to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
18 years - 99 years
All genders
Phase 3
Interventional
Were doing this study to see how T-Guard works compared to ruxolitinib to treat aGVHD that doesnt get better with steroids. We want to know if T-Guard and ruxolitinib therapy will make aGVHD go away completely after 28 days.
341 - 350 of 373